There's one thing I'm trying to square in your testimony. We heard, on the one hand, that lower prices have led to supply issues, and you guys have concerns about that. We also heard you speak positively about not extending drug patents, which have been, as a result, keeping prices low. I'm trying to understand what seems to me to be a tension between advocating for higher prices to maintain supply and expressing pleasure at seeing provisions in the agreement that keep our prices low.
I'm just trying to figure out what my take-away from your testimony should be.